Literature DB >> 11581114

Comparison of the incidence of schizophrenia in rural Dumfries and Galloway and urban Camberwell.

J Allardyce1, J Boydell, J Van Os, G Morrison, D Castle, R M Murray, R G McCreadie.   

Abstract

BACKGROUND: Being born or living in urban areas is associated with high rates of schizophrenia. However, few studies have compared the incidence in urban/rural areas using the same methodology. AIMS: To compare service-based incidence rates for schizophrenia in rural Dumfries and Galloway in south-west Scotland with urban Camberwell in south-east London.
METHOD: Using Research Diagnostic Criteria diagnoses from the OPCRIT computer algorithm, we compared the incidence of schizophrenia over 12 years (1979-1984 and 1992-1997) using indirect standardisation techniques and Poisson regression modelling.
RESULTS: The incidence was 61% higher in urban Camberwell than in rural Dumfries and Galloway (standardised incidence ratio (SIR)=1.61; 95% CI=1.42-1.81). There was no difference in incidence when we compared the White population in Camberwell with Dumfries and Galloway (SIR=1.12; 95% CI=0.86-1.43).
CONCLUSIONS: The incidence of schizophrenia in urban Camberwell was higher than that in rural Dumfries and Galloway; the high incidence of non-Whites in Camberwell largely explains the urban/rural difference.

Entities:  

Mesh:

Year:  2001        PMID: 11581114     DOI: 10.1192/bjp.179.4.335

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  18 in total

1.  Early intervention in first-episode psychosis--the impact of a community development campaign.

Authors:  Helen Krstev; Steve Carbone; Susy M Harrigan; Christina Curry; Kathryn Elkins; Patrick D McGorry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2004-09       Impact factor: 4.328

2.  Migration, cultural bereavement and cultural identity.

Authors:  Dinesh Bhugra; Matthew A Becker
Journal:  World Psychiatry       Date:  2005-02       Impact factor: 49.548

3.  Social defeat and the culture of chronicity: or, why schizophrenia does so well over there and so badly here.

Authors:  T M Luhrmann
Journal:  Cult Med Psychiatry       Date:  2007-06

Review 4.  Schizopsychotic symptom-profiles and biomarkers: beacons in diagnostic labyrinths.

Authors:  Tomas Palomo; Richard M Kostrzewa; Richard J Beninger; Trevor Archer
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 5.  Meta-analysis of the association of urbanicity with schizophrenia.

Authors:  Evangelos Vassos; Carsten B Pedersen; Robin M Murray; David A Collier; Cathryn M Lewis
Journal:  Schizophr Bull       Date:  2012-09-26       Impact factor: 9.306

6.  Ethnic inequalities in the incidence of diagnosis of severe mental illness in England: a systematic review and new meta-analyses for non-affective and affective psychoses.

Authors:  Kristoffer Halvorsrud; James Nazroo; Michaela Otis; Eva Brown Hajdukova; Kamaldeep Bhui
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2019-09-03       Impact factor: 4.328

7.  Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients.

Authors:  Jenn-Huei Renn; Nan-Ping Yang; Pesus Chou
Journal:  BMC Musculoskelet Disord       Date:  2010-02-17       Impact factor: 2.362

8.  Urbanicity, social adversity and psychosis.

Authors:  Andreas Heinz; Lorenz Deserno; Ulrich Reininghaus
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

Review 9.  A review of the reliability and validity of OPCRIT in relation to its use for the routine clinical assessment of mental health patients.

Authors:  Philip J Brittain; Daniel Stahl; James Rucker; Jamie Kawadler; Gunter Schumann
Journal:  Int J Methods Psychiatr Res       Date:  2013-05-09       Impact factor: 4.035

10.  Standardisation of rates using logistic regression: a comparison with the direct method.

Authors:  Andrea K Roalfe; Roger L Holder; Sue Wilson
Journal:  BMC Health Serv Res       Date:  2008-12-29       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.